2021 Molecules of the Year: Nominate!

We’ve just published the final set of Molecules of the Month for 2021, and now it’s time to nominate your favorite molecules for 2021’s Molecules of the Year!

Nominees should have either been first disclosed in 2021 or had a major new update in 2021 (e.g. clinical trial readout, publication, business transaction, approval). The molecule must have a published structure and ideally a publication describing its properties or discovery campaign.

Clinical candidates with interesting profiles, non-clinical molecules with intriguing modes of action, and recently approved drugs can all be nominated. You can nominate your own company’s molecule, but you just can’t vote for it in the final selection.

Most importantly, have fun thinking about it! It’s a great time to reflect on what’s inspired us, and how amazing the science in this industry is.

If you need some inspiration, take a look again at 2020’s Molecules of the Year.

RECENT ARTICLES

DRUG DISCOVERY RESOURCES

JOIN SUBSCRIBERS from

  • Johnson & Johnson
  • Roche
  • Pfizer
  • Novartis
  • Bayer
  • Merck
  • Sanofi
  • GlaxoSmithKline
  • AbbVie
  • Eli Lilly
  • Boehringer Ingelheim
  • Amgen
  • Bristol-Myers Squibb
  • Gilead
  • AstraZeneca
  • Teva
  • Novo Nordisk
  • Merck KGaA
  • Takeda
  • Celgene (BMS)
  • Biogen
  • Astellas
  • Daiichi Sankyo
  • Regeneron
  • UCB
  • Eisai
  • Servier
  • Kyowa Kirin
  • Shionogi
  • Vertex
  • Lundbeck
  • Taisho
  • Ono
  • Seagen
  • Incyte
  • LEO Pharma
  • Janssen
  • Galapagos
  • Idorsia
  • Astex
  • Arvinas
  • Kymera
  • Relay
  • Schrodinger
  • Mirati
  • Revolution
  • Nimbus
  • Plexxikon
  • Forma
  • Arcus
  • RA Capital
  • ARCH Venture Partners
  • MPM Capital
  • Orbimed
  • The Column Group
  • 5AM Ventures
  • Versant Ventures
  • Deerfield
  • Goldman Sachs
  • Citi
  • Piper Sandler
  • Softbank
  • …and hundreds of others